![Nicoletta Loggia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 27 983 $ in data 31/08/2026
Nicoletta Loggia is currently an Independent Director at Candel Therapeutics, Inc. since 2023 and Chief Technical Officer at Orchard Therapeutics Plc since 2021.
Formerly, Dr. Loggia was Head of Cell & Gene Therapies at Novartis AG from 2015 to 2021.
Education includes graduate and doctorate degrees from the University of Pavia.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 30/06/2026 | 2.141 ( 0% ) | 27 983 $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Direttore Tecnico/Scientifico/R&S | 09/09/2021 |
| CANDEL THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 07/06/2023 |
| Società | Posizione | Fine |
|---|---|---|
| NOVARTIS AG | Corporate Officer/Principal | 01/08/2021 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
University of Pavia
 University of Pavia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Candel Therapeutics, Inc.
 Candel Therapeutics, Inc. BiotechnologyHealth Technology Develops and distributes immunotherapies for the treatment of cancer | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc BiotechnologyHealth Technology Engages in research and advancements of gene therapy to develop potential cures for genetic & other severe diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
